{
  "_metadata": {
    "version": "1.0",
    "type": "insights_index",
    "last_updated": "2026-02-13"
  },
  "articles": [
    {
      "slug": "orforglipron-primer",
      "title": "Orforglipron: The First Small-Molecule Oral GLP-1",
      "summary": "A comprehensive primer on the molecule poised to reshape obesity therapeutics â€” from Chugai's polycyclic scaffold to Lilly's NDA submission, the competitive landscape, and the regulatory catalysts ahead in 2026.",
      "category": "catalyst",
      "label": "Deep Dive",
      "date": "2026-02-16",
      "date_display": "February 16, 2026",
      "author": "Satya Bio Research",
      "reading_time": "25 min read",
      "url": "/api/clinical/companies/LLY/insights/orforglipron/html",
      "tickers": ["LLY"],
      "tags": ["GLP-1", "Obesity", "Oral"],
      "key_data": [
        {"key": "Weight Loss", "value": "12.4%"},
        {"key": "PDUFA Date", "value": "Apr 10, 2026"},
        {"key": "Price", "value": "$149/mo"},
        {"key": "Pipeline Assets", "value": "193+"}
      ]
    },
    {
      "slug": "in-vivo-cart-competitive-landscape",
      "title": "In Vivo CAR-T Competitive Landscape",
      "summary": "Interactive tracker of 38+ in vivo CAR-T programs across viral and non-viral delivery. $7.5B+ in M&A, clinical data from 6 programs, and catalysts through 2027.",
      "category": "landscape",
      "label": "Interactive",
      "date": "2026-02-13",
      "date_display": "February 13, 2026",
      "author": "Satya Bio Research",
      "reading_time": "Interactive",
      "tags": ["Landscape", "Interactive"],
      "key_data": [
        {"key": "Programs Tracked", "value": "38+"},
        {"key": "Total M&A", "value": "$7.5B+"},
        {"key": "Clinical Data", "value": "6 programs"},
        {"key": "Pharma Acquirers", "value": "6"}
      ]
    },
    {
      "slug": "fda-moderna-mrna-flu-vaccine",
      "title": "FDA Refuses to File Moderna\u2019s mRNA Influenza Vaccine (mRNA-1010)",
      "summary": "CBER Director Vinay Prasad overruled career FDA reviewers to reject Moderna\u2019s mRNA flu vaccine application. Sector-wide implications for mRNA platform valuation and CBER regulatory risk across vaccines, gene therapies, and cell therapies.",
      "category": "regulatory",
      "label": "Flash Note",
      "date": "2026-02-11",
      "date_display": "February 11, 2026",
      "author": "Satya Bio Research",
      "reading_time": "12 min read",
      "key_data": [
        {"key": "Candidate", "value": "mRNA-1010"},
        {"key": "Phase 3 Efficacy", "value": "+26.6% vs. Standard-Dose"},
        {"key": "Safety Signals", "value": "None Identified"},
        {"key": "Ex-US Status", "value": "Accepted (EU, CA, AU)"}
      ]
    }
  ],
  "categories": {
    "regulatory": {
      "name": "Regulatory",
      "color": "#1b2d45",
      "bg": "rgba(27, 45, 69, 0.08)"
    },
    "landscape": {
      "name": "Landscape",
      "color": "#1b2d45",
      "bg": "rgba(27, 45, 69, 0.06)"
    },
    "deals": {
      "name": "Deals",
      "color": "#d4805a",
      "bg": "rgba(212, 128, 90, 0.08)"
    },
    "catalyst": {
      "name": "Catalyst",
      "color": "#2c4263",
      "bg": "rgba(44, 66, 99, 0.06)"
    }
  }
}
